RIGL · XBRL financial data

Rigel Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RIGL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	28	36*	30	37	55	58*	53	102	69	70*	59	79
Cost of goods and services sold	1	year only	2	3	8	6*	4	5	5	6*	5	9
Research and development	—	year only	—	—	—	year only	8	7	—	year only	12	14
Selling, general and administrative	25	27*	28	28	27	30*	28	29	29	30*	31	33
Operating income (loss)	(4)	2*	(7)	0	14	17*	13	61	28	23*	12	24
Interest income	1	1*	1	1	0	1*	1	1	1	1*	1	1
Interest expense	2	2*	2	2	2	2*	2	2	2	2*	1	1
Income tax expense (benefit)	—	year only	0	0	0	1*	0	0	(0)	(245)*	3	6
Net income (loss)	(6)	1*	(8)	(1)	12	14*	11	60	28	268*	9	17
Earnings per share, basic‡ USD per share	(0.30)	0.00*	(0.50)	(0.06)	0.71	0.81*	0.64	3.33	1.55	14.72*	0.47	0.93
Earnings per share, diluted‡ USD per share	(0.30)	0.00*	(0.50)	(0.06)	0.70	—	0.63	3.28	1.46	13.50*	0.44	0.88
Weighted average shares, basic‡ millions of shares	17	17*	18	18	18	18*	18	18	18	18*	18	19
Weighted average shares, diluted‡ millions of shares	17	17*	18	18	18	18*	18	18	19	20*	20	20

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2024); filings made before it reported them unadjusted.

Fiscal quarters (RIGL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	45	33	26	36	52	57	46	53	49	41	24	61
Short-term investments	17	24	24	13	9	21	31	55	89	114	122	35
Accounts receivable	24	31	28	29	31	42	42	40	46	52	50	56
Inventory	6	6	7	8	5	6	5	10	13	12	12	14
Prepaid and other current assets	3	6	9	9	10	10	23	17	19	22	26	20
Total current assets	95	99	92	95	106	135	147	175	215	240	234	186
Property and equipment, net	0	0	0	0	0	0	0	0	0	0	—	—
Right-of-use asset	1	1	1	1	0	0	1	1	1	1	1	1
Total assets	115	117	127	128	139	164	176	207	243	514	505	521
Accounts payable	8	7	9	6	4	3	4	7	4	7	4	4
Total current liabilities	48	53	73	59	54	63	67	87	94	99	89	96
Lease liability, non-current	0	0	0	—	—	0	1	1	1	0	0	0
Total liabilities	147	146	158	158	154	161	157	125	125	122	105	96
Accumulated deficit	(1,408)	(1,408)	(1,416)	(1,417)	(1,404)	(1,390)	(1,379)	(1,319)	(1,291)	(1,023)	(1,014)	(997)
Total stockholders' equity	(32)	(29)	(32)	(30)	(15)	3	19	82	118	391	400	425
Total liabilities and equity	115	117	127	128	139	164	176	207	243	514	505	521
Common shares outstanding (cover page)‡ millions of shares	17	18	18	18	18	18	18	18	18	18	19	19

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2024); filings made before it reported them unadjusted.

Fiscal quarters (RIGL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(6)	1*	(8)	(1)	12	14*	11	60	28	268*	9	17
Stock-based compensation	2*	2*	5	3*	3*	2*	3	3*	3*	3*	3	7*
Depreciation and amortization	0*	0*	0	1*	1*	1*	1	1*	1*	1*	1	1*
Net cash from operating activities	(1)*	(6)*	(5)	0*	22*	15*	(1)	31*	24*	22*	3	31*
Net cash from investing activities	(1)*	(7)*	0	11*	4*	(11)*	(11)	(23)*	(33)*	(25)*	(8)	17*
Share repurchases	—	—	—	—	—	—	0	0*	—	—	4	1*
Net cash from financing activities	(1)*	0*	(3)	(1)*	(10)*	1*	0	0*	4*	(5)*	(11)	(12)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Rigel Pharmaceuticals	61	79	31*	18.7M	—	Q2 FY26 10-QJun 30, 2026
Amarin	157	40	9.2*	not reported	—	Q3 FY26 10-QSep 30, 2026
Usana Health Sciences	169	223	23*	18.5M	—	Q2 FY26 10-QJul 4, 2026
Altimmune	63	not reported	(24)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288	1	(25)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Avadel Pharmaceuticals	80	77	22*	97.7M	—	Q3 FY25 10-QSep 30, 2025
Northwest Biotherapeutics	0.6	0.8	(7.2)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	68	not reported	(33)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Emergent BioSolutions	176	110	100*	51.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.